戻る Agenda
Session 3: Good Compliance is Good Business
Session Chair(s)
Francine Lane, MBA
Senior Director of Product Management
Citeline, United States
The public continues to pay close attention to clinical trial disclosures. Large pharma is no longer the primary focus of analyses by transparency advocates but studies from organizations from all sizes and shapes are highlighted when study results are not shared in a timely manner. In this session, we’ll hear from funders and transparency advocates to understand why disclosure is important, what is ‘good’ compliance, and some best practices to help your organization become better with clinical trial disclosures and compliance.
Learning Objective : At the conclusion of this session, participants should be able to:- Identify major stakeholders for clinical trial disclosure information
- Assess why good compliance is important to different stakeholder groups
- Discuss best practices to achieve good compliance
Speaker(s)
Why Transparency is Important to Us (Remote Presentation)
Georgina Humphreys, PhD, MSc
Wellcome Trust, United Kingdom
Clinical Data Sharing Manager
Trends and Best Practices in Trial Disclosure
Thomas Wicks, MBA
Citeline, United States
Head of Transparency Operations
Evolving Transparency Expectations: The Road Ahead (Remote Presentation)
Till Bruckner, PhD
TranspariMED, United Kingdom
Founder